Sara Hitchman, OD
Optometrist · Cleveland, OHNPI 1790215523
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. GSK accounts for 65.6% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $13,265 and has fallen 84.0% since, to $2,129 in 2025. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $126.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$13K
- Coopervision Inc.$1K
- Bausch & Lomb Americas Inc.$960
- Johnson & Johnson Vision Care, Inc.$651
- AbbVie$642
- Oyster Point Pharma, Inc.$607
- plus $3K from 17 others
What the payments were for
- Consulting fees$1,99510%
- Speaking & faculty fees$8,25041%
- Travel & lodging$2,89614%
- Food & beverage$6,86034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $13,125 |
| Coopervision Inc. | 15 | $1,248 |
| Bausch & Lomb Americas Inc. | 12 | $960 |
| Johnson & Johnson Vision Care, Inc. | 11 | $651 |
| AbbVie(2 entities) | 18 | $642 |
| Oyster Point Pharma, Inc. | 9 | $607 |
| Sun Pharmaceutical Industries Inc. | 26 | $551 |
| Alcon | 11 | $509 |
| Biotissue Holdings Inc. | 5 | $355 |
| Tarsus Pharmaceuticals, Inc. | 10 | $308 |
| Novartis | 3 | $204 |
| Dompe US, Inc. | 3 | $171 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Shire North American Group Inc | 2 | $124 |
| Harrow Eye, LLC | 4 | $95 |
| Quidel Corporation | 1 | $90 |
| Alimera Sciences, Inc. | 4 | $67 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $60 |
| Carl Zeiss Meditec, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$12,981
- INFUSE$444
- Onefit Contact Lens$395
- TYRVAYA$316
- Acuvue$220
- XIIDRA$220
- BIOTRUE$218
- Precision7$132
- ScoutPro Osmolarity System$131
- Prokera$127
- AmnioGraft$127
- ALDEN SCLERAL ZENLENS$125
- Oxervate$125
- RESTASIS$125
- Rhopressa$124
- Rocklatan$124
- XDEMVY$124
- MyDay Contact Lens$123
- CEQUA$113
- Paragon CRT$113
How this compares
$20,001 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 86 | $88,538 |
| XiidraLifitegrast | 47 | $49,486 |
| CequaCyclosporine | 59 | $44,285 |
| TyrvayaVarenicline Tartrate | 27 | $22,283 |
| Restasis MultidoseCyclosporine | 22 | $17,381 |
| Cyclosporine | 35 | $13,898 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $1,621 |
| Prednisolone Acetate | 28 | $1,166 |
| Fluorometholone | 12 | $672 |
| Latanoprost | 125 | $562 |
| Brimonidine Tartrate | 18 | $507 |
| Doxycycline Hyclate | 21 | $336 |
| Timolol Maleate | 74 | $284 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose | $642 | $105,919108 claims |
| Bausch & Lomb Americas Inc.Xiidra | $960 | $49,48647 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $551 | $44,28559 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $607 | $22,28327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Cleveland
- Thomas ChesterCleveland$300K
- Loretta Szczotka-FlynnCleveland$14K
- Thomas StokkermansCleveland$12K
- Joseph KeaneyCleveland$11K
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.